Literature DB >> 1568177

Medical risk factors and the development of brain tumors.

B Schlehofer1, M Blettner, N Becker, C Martinsohn, J Wahrendorf.   

Abstract

Several diseases and medical treatments are discussed as risk factors for the development of brain tumors. A population-based case-control study in the Rhein-Neckar-Odenwald area (containing 1.3 million inhabitants) of Germany was established to investigate this question. A total of 226 patients (cases) with primary brain tumors (International Classification of Diseases, ninth edition, classes 191, 191.1, and 192.0) and 418 control subjects (controls) were interviewed using a standardized questionnaire over a period of 2 years. No association was seen for head injuries, hereditary diseases, family history, and radiographic examination of the head and teeth. However, more cases than controls had had meningitis (relative risk [RR], 2.7; 95% confidence interval [CI], 0.9 to 8.6) or epilepsy (RR, 2.6; 95% CI, 0.6 to 11.7). The RR was decreased for those who had allergic diseases (RR, 0.7; 95% CI, 0.5 to 1.0), diabetes (RR, 0.7; 95% CI, 0.3 to 1.8), and infections and colds (RR, 0.3; 95% CI, 0.1 to 0.8).

Entities:  

Mesh:

Year:  1992        PMID: 1568177     DOI: 10.1002/1097-0142(19920515)69:10<2541::aid-cncr2820691025>3.0.co;2-h

Source DB:  PubMed          Journal:  Cancer        ISSN: 0008-543X            Impact factor:   6.860


  26 in total

1.  Lack of association of herpesviruses with brain tumors.

Authors:  S Poltermann; B Schlehofer; K Steindorf; P Schnitzler; K Geletneky; J R Schlehofer
Journal:  J Neurovirol       Date:  2006-04       Impact factor: 2.643

2.  Association and interactions between DNA repair gene polymorphisms and adult glioma.

Authors:  Yanhong Liu; Michael E Scheurer; Randa El-Zein; Yumei Cao; Kim-Anh Do; Mark Gilbert; Kenneth D Aldape; Qingyi Wei; Carol Etzel; Melissa L Bondy
Journal:  Cancer Epidemiol Biomarkers Prev       Date:  2009-01       Impact factor: 4.254

3.  Allergic conditions reduce the risk of glioma: a meta-analysis based on 128,936 subjects.

Authors:  Hongyu Zhao; Weisong Cai; Shitao Su; Debao Zhi; Jie Lu; Shuo Liu
Journal:  Tumour Biol       Date:  2013-12-18

Review 4.  Environmental risk factors for primary malignant brain tumors: a review.

Authors:  M Wrensch; M L Bondy; J Wiencke; M Yost
Journal:  J Neurooncol       Date:  1993-07       Impact factor: 4.130

5.  Effects of antihistamine and anti-inflammatory medication use on risk of specific glioma histologies.

Authors:  Michael E Scheurer; E Susan Amirian; Stacy L Davlin; Terri Rice; Margaret Wrensch; Melissa L Bondy
Journal:  Int J Cancer       Date:  2011-04-04       Impact factor: 7.396

Review 6.  Season of birth and risk for adult onset glioma.

Authors:  Jimmy T Efird
Journal:  Int J Environ Res Public Health       Date:  2010-04-28       Impact factor: 3.390

Review 7.  Epidemiology and etiology of meningioma.

Authors:  Joseph Wiemels; Margaret Wrensch; Elizabeth B Claus
Journal:  J Neurooncol       Date:  2010-09-07       Impact factor: 4.130

8.  Occupational exposure to pesticides and risk of adult brain tumors.

Authors:  Claudine M Samanic; Anneclaire J De Roos; Patricia A Stewart; Preetha Rajaraman; Martha A Waters; Peter D Inskip
Journal:  Am J Epidemiol       Date:  2008-02-24       Impact factor: 4.897

9.  Common variation in genes related to innate immunity and risk of adult glioma.

Authors:  Preetha Rajaraman; Alina V Brenner; Mary Ann Butler; Sophia S Wang; Ruth M Pfeiffer; Avima M Ruder; Martha S Linet; Meredith Yeager; Zhaoming Wang; Nick Orr; Howard A Fine; Deukwoo Kwon; Gilles Thomas; Nathaniel Rothman; Peter D Inskip; Stephen J Chanock
Journal:  Cancer Epidemiol Biomarkers Prev       Date:  2009-05       Impact factor: 4.254

10.  Long-term anti-inflammatory and antihistamine medication use and adult glioma risk.

Authors:  Michael E Scheurer; Randa El-Zein; Patricia A Thompson; Kenneth D Aldape; Victor A Levin; Mark R Gilbert; Jeffrey S Weinberg; Melissa L Bondy
Journal:  Cancer Epidemiol Biomarkers Prev       Date:  2008-05       Impact factor: 4.254

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.